The 2-year local recurrence-free survival (LRFS) improved from 76.0% without adjuvant RT to 87.1% with it. Disease-free (DFS) ...

Immunocompromised patients with bladder cancer who undergo TURBT followed by BCG immunotherapy have worse survival outcomes compared to non-immunocompromised patients, a study suggests.

Adjuvant radiotherapy could substantially reduce risk for locoregional recurrence for patients with advanced muscle-invasive ...

Radiation therapy could be an underused tool to reduce pelvic relapse risk for patients with locally advanced, ...

Discover a study analysing real-world use of neoadjuvant chemotherapy in muscle-invasive bladder cancer and its impact on ...

TAR-200 demonstrated a high disease-free survival and bladder preservation rates in BCG-unresponsive, high-risk non-muscle-invasive bladder cancer. TAR-200, an intravesical chemotherapy releasing ...

Adding TAR-200 to neoadjuvant cetrelimab improved the pCR rate in patients with muscle-invasive bladder cancer in a phase 2 trial.

Pfizer Inc. (NYSE:PFE) is one of the best dividend stocks to buy. On August 12, Pfizer and Astellas Pharma reported that their combination therapy for muscle-invasive bladder cancer had positive ...

PADCEV plus KEYTRUDA is the first and only regimen to improve survival when used before and after standard of care (surgical cystectomy) in cisplatin-ineligible patients with muscle-invasive bladder ...